ClinicalTrials.gg
Sign In

Ependymoma clinical trials

The registry lists 224 studies for Ependymoma across more than 10 countries. 35 are recruiting or about to start. 42 of them are mainly about Ependymoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Ependymoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
113
Terminated
31
Active, not recruiting
26
Recruiting
24
Withdrawn
12
Not yet recruiting
11

Phase

Phase 1
95
Phase 2
88
Early Phase 1
8
Phase 3
6

Where

United States
182
Canada
16
Puerto Rico
14
Australia
11
France
9
Spain
8

Who runs them

National Cancer Institute (NCI) (34) · M.D. Anderson Cancer Center (8) · Wake Forest University Health Sciences (7) · Children's Oncology Group (7) · City of Hope Medical Center (7) · Case Comprehensive Cancer Center (6) · St. Jude Children's Research Hospital (6) · Duke University (5)

What is being tested here

Drugs under test in Ependymoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
AZD 6244204
Lutetium Lu 177 dotatate202
Temozolomide1120
Etoposide126
Irinotecan104
Cyclophosphamide114
Olaparib103
ONC206102
G 207102
Oncolytic HSV-1 G207102

Drug classes tested here Alkylating agents 2 open · Immune checkpoint inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 1 open · PARP inhibitors 1 open · Antimetabolites 10

Coming up

0phase 3 studies under way
9studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9

Who these studies take

Of the 24 Ependymoma studies recruiting now, 7 (29%) set no upper age limit and 15 (63%) stop at 75 or younger. 18 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (4%) take healthy volunteers.

Recruiting studies that take each age, of 24
AgeWomenMen
1017 (71%)17 (71%)
1824 (100%)24 (100%)
3014 (58%)14 (58%)
4010 (42%)10 (42%)
5010 (42%)10 (42%)
6510 (42%)10 (42%)
7510 (42%)10 (42%)
858 (33%)8 (33%)

Across all 224 studies, recruiting or not: 52% stop at 75 or younger and 49% at 65; 59% take children; 0% are for women only and <1% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Ependymoma studies take

Of 42 phase 1 interventional studies under Ependymoma, half reached primary completion within 62 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 162 mo39–92 · 42 studies—65 mo39–92 · 36 studies
Phase 267 mo52–108 · 35 studies—66 mo47–108 · 34 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 224. Browse all 224 → or search them.